How CBD and THC Interfere with Common Medications: A Controlled Human Study

A CBD-dominant cannabis brownie significantly inhibited four major drug-metabolizing enzymes in healthy adults, meaning CBD could increase blood levels of many common medications — THC alone had minimal effects.

Bansal, Sumit et al.·Clinical pharmacology and therapeutics·2023·Moderate EvidenceRandomized Controlled Trial·1 min read
RTHC-04397Randomized Controlled TrialModerate Evidence2023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
N=18
Participants
N=18 healthy adults, aged 18-50, US participants

What This Study Found

When you take a medication, your liver enzymes (called cytochrome P450 or CYP enzymes) break it down. If something inhibits those enzymes, the medication stays in your blood longer and at higher levels — potentially causing side effects or toxicity. This study is one of the first controlled human trials to measure exactly how cannabis cannabinoids affect these critical drug-metabolizing enzymes.

Eighteen healthy adults participated in a randomized crossover study. Each person ate, on separate occasions separated by at least one week: a placebo brownie, a CBD-dominant brownie (640 mg CBD + 20 mg THC), or a THC-only brownie (20 mg THC). Thirty minutes after the brownie, they consumed a 'drug cocktail' of five probe medications, each metabolized by a different CYP enzyme: caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A).

The CBD brownie significantly inhibited four of the five enzymes, with CYP2C19 most strongly affected, followed by CYP2C9, CYP3A, and CYP1A2. Only CYP2D6 was spared. The THC-only brownie had minimal effects on any of the enzymes.

This matters because CYP2C19 metabolizes common medications like clopidogrel (blood thinner), some antidepressants, and proton pump inhibitors. CYP2C9 handles warfarin and some anti-inflammatory drugs. CYP3A metabolizes about half of all prescription drugs. If CBD is inhibiting these enzymes, patients taking CBD alongside these medications could be getting higher-than-intended drug levels.

Key Numbers

18 healthy adults in a crossover design. CBD dose: 640 mg (a high but not uncommon supplement dose) + 20 mg THC. CBD brownie inhibited CYP2C19 (strongest), CYP2C9, CYP3A, and CYP1A2. CYP2D6 was not significantly affected. THC-only brownie (20 mg) showed no significant enzyme inhibition. Blood and urine collected over 24 hours.

How They Did This

Randomized, three-way crossover study in 18 healthy adults. Participants received, in random order with ≥1 week washout: (1) placebo brownie, (2) CBD-dominant brownie (640 mg CBD + 20 mg THC), or (3) THC-dominant brownie (20 mg THC). Thirty minutes post-brownie, participants consumed a validated CYP probe drug cocktail (caffeine, losartan, omeprazole, dextromethorphan, midazolam). Plasma and urine were collected over 24 hours to measure enzyme activity through probe drug metabolism.

Why This Research Matters

Millions of people use CBD products — often alongside prescription medications — with little awareness of potential drug interactions. This is the first well-controlled human study using actual cannabis extracts (not isolated pharmaceutical CBD) to quantify these interactions. The finding that CBD inhibits four major metabolic pathways has immediate clinical relevance for anyone combining CBD with prescription drugs, particularly blood thinners, antidepressants, anti-seizure medications, and immunosuppressants.

The Bigger Picture

This study provides the controlled human data that explains mechanisms observed in RTHC-00078 (cannabis users on buprenorphine had 2.7x higher drug levels). It also connects to the drug interaction monitoring in RTHC-00085 (THC/CBD for dementia patients on multiple medications). For the growing population using CBD alongside prescriptions — especially elderly patients on polypharmacy — these enzyme inhibition findings have immediate practical implications.

What This Study Doesn't Tell Us

Single-dose study in healthy young adults — chronic CBD users or elderly/sick patients may show different interaction profiles. The CBD dose (640 mg) is high compared to typical consumer CBD products (25–100 mg), though some medical uses approach this level. The probe drug cocktail measures enzyme activity, not clinical outcomes — inhibiting an enzyme doesn't automatically mean a dangerous interaction with every drug that enzyme handles. Real-world cannabis products have variable CBD content and additional compounds that could modify these effects.

Questions This Raises

  • ?At what CBD dose do clinically meaningful drug interactions begin?
  • ?Do lower CBD doses (50–100 mg, typical supplements) still inhibit these enzymes?
  • ?Should patients on warfarin, clopidogrel, or immunosuppressants be explicitly warned about CBD products?
  • ?Can CBD enzyme inhibition be used therapeutically to boost drug levels intentionally (similar to how grapefruit juice interactions are sometimes leveraged)?

Trust & Context

Key Stat:
Evidence Grade:
This is a well-designed randomized crossover trial in healthy adults — one of the strongest designs for pharmacokinetic studies. The crossover means each person served as their own control, reducing variability. The evidence for enzyme inhibition is solid; clinical implications need further study.
Study Age:
Published in 2023. This is among the first controlled human studies of cannabis-drug interactions using actual cannabis extracts rather than isolated compounds.
Original Title:
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Published In:
Clinical pharmacology and therapeutics, 114(3), 693-703 (2023)Clinical Pharmacology and Therapeutics is a reputable journal focusing on the science of drug therapy.
Database ID:
RTHC-04397

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-04397·https://rethinkthc.com/research/RTHC-04397

APA

Bansal, Sumit; Zamarripa, C Austin; Spindle, Tory R; Weerts, Elise M; Thummel, Kenneth E; Vandrey, Ryan; Paine, Mary F; Unadkat, Jashvant D. (2023). Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.. Clinical pharmacology and therapeutics, 114(3), 693-703. https://doi.org/10.1002/cpt.2973

MLA

Bansal, Sumit, et al. "Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.." Clinical pharmacology and therapeutics, 2023. https://doi.org/10.1002/cpt.2973

RethinkTHC

RethinkTHC Research Database. "Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Inte..." RTHC-04397. Retrieved from https://rethinkthc.com/research/bansal-2023-evaluation-of-cytochrome-p450mediated

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.